Angelica Tiotiu1,2, Iulia Ioan2,3, Nathalie Wirth1, Rodrigo Romero-Fernandez4, Francisco-Javier González-Barcala5,6,7,8. 1. Department of Pulmonology, University Hospital of Nancy, 54511 Nancy, France. 2. Development, Adaptation and Disadvantage, Cardiorespiratory Regulations and Motor Control (EA 3450 DevAH), University of Lorraine, 54505 Nancy, France. 3. Lung Function Testing Lab, Children's University Hospital, 8 Rue du Morvan, 54511 Vandoeuvre-lès-Nancy, France. 4. Department of Medicine, Clinic University Hospital, Santiago de Compostela, 15706 Santiago de Compostela, Spain. 5. Department of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain. 6. Spanish Biomedical Research Networking Centre-CIBERES, 15706 Santiago de Compostela, Spain. 7. Department of Respiratory Medicine, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain. 8. Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain.
Abstract
Background: Tobacco smoking is associated with more severe asthma symptoms, an accelerated decline in lung function, and reduced responses to corticosteroids. Our objective was to compare asthma outcomes in terms of disease control, exacerbation rates, and lung function in a population of asthmatic patients according to their smoking status. Methods: We compared patients' demographics, disease characteristics, and lung-function parameters in current-smokers (CS, n = 48), former-smokers (FS, n = 38), and never-smokers (NS, n = 90), and identified predictive factors for asthma control. Results: CS had a higher prevalence of family asthma/atopy, a lower rate of controlled asthma, impaired perception of dyspnea, an increased number of exacerbations, and poorer lung function compared to NS. The mean asthma control questionnaire's (ACQ) score was higher in CS vs. NS and FS (1.9 vs. 1.2, p = 0.02). Compared to CS, FS had a lower rate of exacerbations, a better ACQ score (similar to NS), a higher prevalence of dyspnea, and greater lung-diffusion capacity. Non-smoking status, the absence of dyspnea and exacerbations, and a forced expiratory volume in one second ≥80% of predicted were associated with controlled asthma. Conclusions: CS with asthma exhibit worse clinical and functional respiratory outcomes compared to NS and FS, supporting the importance of smoking cessation in this population.
Background: Tobacco smoking is associated with more severe asthma symptoms, an accelerated decline in lung function, and reduced responses to corticosteroids. Our objective was to compare asthma outcomes in terms of disease control, exacerbation rates, and lung function in a population of asthmatic patients according to their smoking status. Methods: We compared patients' demographics, disease characteristics, and lung-function parameters in current-smokers (CS, n = 48), former-smokers (FS, n = 38), and never-smokers (NS, n = 90), and identified predictive factors for asthma control. Results:CS had a higher prevalence of family asthma/atopy, a lower rate of controlled asthma, impaired perception of dyspnea, an increased number of exacerbations, and poorer lung function compared to NS. The mean asthma control questionnaire's (ACQ) score was higher in CS vs. NS and FS (1.9 vs. 1.2, p = 0.02). Compared to CS, FS had a lower rate of exacerbations, a better ACQ score (similar to NS), a higher prevalence of dyspnea, and greater lung-diffusion capacity. Non-smoking status, the absence of dyspnea and exacerbations, and a forced expiratory volume in one second ≥80% of predicted were associated with controlled asthma. Conclusions: CS with asthma exhibit worse clinical and functional respiratory outcomes compared to NS and FS, supporting the importance of smoking cessation in this population.
Authors: N Macintyre; R O Crapo; G Viegi; D C Johnson; C P M van der Grinten; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; P Gustafsson; J Hankinson; R Jensen; R McKay; M R Miller; D Navajas; O F Pedersen; R Pellegrino; J Wanger Journal: Eur Respir J Date: 2005-10 Impact factor: 16.671
Authors: Rekha Chaudhuri; Eric Livingston; Alex D McMahon; Jane Lafferty; Iona Fraser; Mark Spears; Charles P McSharry; Neil C Thomson Journal: Am J Respir Crit Care Med Date: 2006-04-27 Impact factor: 21.405
Authors: Stephen C Lazarus; Vernon M Chinchilli; Nancy J Rollings; Homer A Boushey; Reuben Cherniack; Timothy J Craig; Aaron Deykin; Emily DiMango; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Robert F Lemanske; Frank T Leone; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Michael E Wechsler; John V Fahy Journal: Am J Respir Crit Care Med Date: 2007-01-04 Impact factor: 21.405
Authors: Aparna Balasubramanian; Neil R MacIntyre; Robert J Henderson; Robert L Jensen; Gregory Kinney; William W Stringer; Craig P Hersh; Russell P Bowler; Richard Casaburi; MeiLan K Han; Janos Porszasz; R Graham Barr; Barry J Make; Robert A Wise; Meredith C McCormack Journal: Chest Date: 2019-07-25 Impact factor: 9.410
Authors: Jouni J K Jaakkola; Samu Hernberg; Taina K Lajunen; Penpatra Sripaijboonkij; L Pekka Malmberg; Maritta S Jaakkola Journal: BMJ Open Respir Res Date: 2019-03-25